Timing of Adolescent Meningococcal Conjugate Vaccination

Attitudes and Practices of Pediatricians and Family Medicine Physicians


      The meningococcal conjugate vaccine (MCV4) was recommended for those aged 11–18 years in 2005. Initial supply issues led to an emphasis on immunizing older adolescents. When supply improved in 2007, routine immunization was recommended for those aged 11–12 years.


      Among a U.S. sample of pediatricians and family medicine physicians, describe (1) recommendation and administration practices for MCV4; (2) preferences regarding MCV4 administration; and (3) attitudes and characteristics associated with recommendation for those aged >12 years.


      A mail and Internet survey in a nationally representative sample of physicians was conducted between December 2009 and March 2010. Analysis was conducted between March 2010 and October 2010, including a multivariable analysis to examine factors associated with deferring MCV4 to ages >12 years.


      Response rates were 88% (pediatricians 367/419) and 63% (family medicine physicians 268/423). In all, 95% of pediatricians and 73% of family medicine physicians reported administering MCV4 routinely to those aged 11–18 years (p<0.0001); 83% (pediatricians) and 45% (family medicine physicians) reported strongly recommending MCV4 for those aged 11–12 years (p<0.0001); 27% (pediatricians) and 40% (family medicine physicians) preferred to administer MCV4 to those aged >12 years (p<0.0001). Compared with those who strongly recommend for those aged 11–12 years, physicians who do not regularly stock MCV4, family medicine physicians, and physicians concerned about waning immunity were more likely to defer their recommendation, whereas physicians practicing in the Northeast and those with more Latino patients were less likely to defer.


      Most pediatricians and family medicine physicians administer MCV4, but many, especially family medicine physicians and those concerned about waning immunity, defer their recommendation for MCV4 to patients aged >12 years.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Preventive Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Cohn A.C.
        • MacNeil J.R.
        • Harrison L.H.
        • et al.
        Changes in Neisseria meningitidis disease epidemiology in the U.S., 1998-2007: implications for prevention of meningococcal disease.
        Clin Infect Dis. 2010; 50: 184-191
        • Bruce M.G.
        • Rosenstein N.E.
        • Capparella J.M.
        • Shutt K.A.
        • Perkins B.A.
        • Collins M.
        Risk factors for meningococcal disease in college students.
        JAMA. 2001; 286: 688-693
        • Bilukha O.O.
        • Rosenstein N.
        Prevention and control of meningococcal disease.
        MMWR Recomm Rep. 2005; 54: 1-21
        • American Academy of Pediatrics Committee on Infectious Diseases
        Prevention and control of meningococcal disease: recommendations for use of meningococcal vaccines in pediatric patients.
        Pediatrics. 2005; 116: 496-505
        • Kimmel S.R.
        Prevention of meningococcal disease.
        Am Fam Physician. 2005; 72: 2049-2056
        • CDC
        Limited supply of meningococcal conjugate vaccine, recommendation to defer vaccination of persons aged 11–12 years.
        MMWR Morb Mortal Wkly Rep. 2006; 55: 567-568
        • CDC
        Revised recommendations of the Advisory Committee on Immunization Practices to vaccinate all persons aged 11–18 years with meningococcal conjugate vaccine.
        MMWR Morb Mortal Wkly Rep. 2007; 56: 794-795
        • CDC
        Licensure of a meningococcal conjugate vaccine (Menveo) and guidance for use—Advisory Committee on Immunization Practices (ACIP), 2010.
        MMWR Morb Mortal Wkly Rep. 2010; 59: 273
      1. Advisory Committee on Immunization Practices Meeting.
        CDC, Atlanta, GeorgiaOctober 27–28, 2010
        • Clark S.J.
        • Cowan A.E.
        • Stokley S.
        • Bilukha O.
        • Davis M.M.
        Physician perspectives to inform a new recommendation for meningococcal conjugate vaccine (MCV4).
        J Adolesc Health. 2006; 39: 850-855
        • Ford C.A.
        • English A.
        • Davenport A.F.
        • Stinnett A.J.
        Increasing adolescent vaccination: barriers and strategies in the context of policy, legal, and financial issues.
        J Adolesc Health. 2009; 44: 568-574
        • Humiston S.G.
        • Albertin C.
        • Schaffer S.
        • et al.
        Health care provider attitudes and practices regarding adolescent immunizations: a qualitative study.
        Patient Educ Couns. 2009; 75: 121-127
        • Lu P.J.
        • Jain N.
        • Cohn A.C.
        Meningococcal conjugate vaccination among adolescents aged 13–17 years, U.S., 2007.
        Vaccine. 2010; 28: 2350-2355
        • CDC
        National, state, and local area vaccination coverage among adolescents aged 13–17 years—U.S., 2008.
        MMWR Morb Mortal Wkly Rep. 2009; 58: 997-1001
        • CDC
        National, state, and local area vaccination coverage among adolescents aged 13–17 years—U.S., 2009.
        MMWR Morb Mortal Wkly Rep. 2010; 59: 1018-1023
        • Crane L.A.
        • Daley M.F.
        • Barrow J.
        • et al.
        Sentinel physician networks as a technique for rapid immunization policy surveys.
        Eval Health Prof. 2008; 31: 43-64
        • Babbie E.
        The practice of social research.
        4th ed. Wadsworth Publishing, Belmont CA1986
        • McMahon S.R.
        • Iwamoto M.
        • Massoudi M.S.
        • et al.
        Comparison of e-mail, fax, and postal surveys of pediatricians.
        Pediatrics. 2003; 111: e299-e303
        • Zhang J.
        • Yu K.F.
        What's the relative risk?.
        JAMA. 1998; 280: 1690-1691
        • Kleinman L.C.
        • Norton E.C.
        What's the risk?.
        Health Serv Res. 2009; 44: 288-302
        • Schaffer S.J.
        • Humiston S.G.
        • Shone L.P.
        • Averhoff F.M.
        • Szilagyi P.G.
        Adolescent immunization practices: a national survey of U.S. physicians.
        Arch Pediatr Adolesc Med. 2001; 155: 566-571
        • Immunization Action Coalition
        State mandates on immunization and vaccine-preventable diseases.
        • Dempsey A.F.
        • Cowan A.E.
        • Broder K.R.
        • Kretsinger K.
        • Stokley S.
        • Clark S.J.
        Adolescent Tdap vaccine use among primary care physicians.
        J Adolesc Health. 2009; 44: 387-393
        • Oster N.V.
        • McPhillips-Tangum C.A.
        • Averhoff F.
        • Howell K.
        Barriers to adolescent immunization: a survey of family physicians and pediatricians.
        J Am Board Fam Pract. 2005; 18: 13-19
        • Davis M.M.
        • Broder K.R.
        • Cowan A.E.
        • et al.
        Physician attitudes and preferences about combined Tdap vaccines for adolescents.
        Am J Prev Med. 2006; 31: 176-180
        • Freed G.L.
        • Nahra T.A.
        • Wheeler J.R.
        Which physicians are providing health care to America's children?.
        Arch Pediatr Adolesc Med. 2004; 158: 22-26
        • Rand C.M.
        • Shone L.P.
        • Albertin C.
        • Auinger P.
        • Klein J.D.
        • Szilagyi P.G.
        National health care visit patterns of adolescents: implications for delivery of new adolescent vaccines.
        Arch Pediatr Adolesc Med. 2007; 161: 252-259
        • Campos-Outcalt D.
        • Jeffcott-Pera M.
        • Carter-Smith P.
        • Schoof B.K.
        • Young H.F.
        Vaccines provided by family physicians.
        Ann Fam Med. 2010; 8: 507-510
        • Fryer G.E.
        • Green L.A.
        • Dovey S.M.
        • Phillips Jr, R.I.
        The U.S. relies on family physicians unlike any other specialty.
        Am Fam Physician. 2001; 63: 1669
        • Pollard A.J.
        • Perrett K.P.
        • Beverley P.C.
        Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines.
        Nat Rev Immunol. 2009; 9: 213-220
        • CDC
        Updated recommendations for use of meningococcal conjugate vaccines—Advisory Committee on Immunization Practices (ACIP), 2010.
        MMWR Morb Mortal Wkly Rep. 2011; 60: 72-76
        • Pelton S.I.
        • Gilmet G.P.
        Expanding prevention of invasive meningococcal disease.
        Expert Rev Vaccines. 2009; 8: 717-727
        • Snape M.D.
        • Kelly D.F.
        • Salt P.
        • et al.
        Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization.
        Clin Infect Dis. 2006; 43: 1387-1394
        • Stokley S.
        • Freed G.
        • Curtis R.
        • et al.
        Adolescent vaccination: recommendations from the National Vaccine Advisory Committee.
        Am J Prev Med. 2009; 36 (278–9e6)
        • Daley M.F.
        • Crane L.A.
        • Markowitz L.E.
        • et al.
        Human papillomavirus vaccination practices: a survey of U.S. physicians 18 months after licensure.
        Pediatrics. 2010; 126: 425-433
        • Rupp R.
        • Rosenthal S.L.
        • Middleman A.B.
        Vaccination: an opportunity to enhance early adolescent preventative services.
        J Adolesc Health. 2006; 39: 461-464
        • Szilagyi P.G.
        • Rand C.M.
        • McLaurin J.
        • et al.
        • Working Group on Adolescent Vaccination in the Medical Home
        Delivering adolescent vaccinations in the medical home: a new era?.
        Pediatrics. 2008; 121: S15-S24
        • CDC
        Recommended immunization schedule for persons aged 7 through 18 years—U.S..